RANI — Rani Therapeutics Holdings Income Statement
0.000.00%
Last trade - 00:00- $117.86m
- $121.30m
- $1.03m
Annual income statement for Rani Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.462 | 2.72 | 0 | 0 | 1.03 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 17 | 55 | 63.5 | 66.1 | 54.3 |
| Operating Profit | -16.5 | -52.3 | -63.5 | -66.1 | -53.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -16.7 | -53 | -63.3 | -67.9 | -56.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.7 | -53.1 | -63.3 | -67.9 | -56.6 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.7 | -8.33 | -30.6 | -34 | -30 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.7 | -8.33 | -30.6 | -34 | -30 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.348 | -0.403 | -1.28 | -1.33 | -0.924 |
| Dividends per Share |